Why the study?
Do new antiarrhythmic drugs safely treat cardiac arrhythmias without increasing mortality?
Population
Patients with cardiac arrhythmia, particularly ventricular premature complexes or malignant arrhythmias
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports caution with flecainide and encainide for ventricular arrhythmias; leaves open mortality effects of new antiarrhythmics until trial data emerge.
Structured PICO
Do new antiarrhythmic drugs safely treat cardiac arrhythmias without increasing mortality?
P
Population
Patients with cardiac arrhythmia, particularly ventricular premature complexes or malignant arrhythmias
I
Intervention
New antiarrhythmic drugs (flecainide, encainide)
Caution is advised when prescribing new antiarrhythmic drugs like flecainide and encainide due to proarrhythmic risks, pending results from mortality trials.
Cite This Study
Jeffrey L. Anderson (1988) studied this question.